← Evidence map

TrialNephrology (Carlton, Vic.)2025

Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.

Simon D Roger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. | OpenQuestion